Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D05VCA
|
||||
| Former ID |
DIB009997
|
||||
| Drug Name |
IP10.C8-1
|
||||
| Synonyms |
DPIV/AAP inhibitor (PETIR, tranplant rejection), IMTM; IP10.C8-1 (PETIR, tranplant rejection), IMTM
|
||||
| Indication | Psoriasis [ICD9: 696; ICD10:L40] | Phase 2 | [530043] | ||
| Company |
Immunotech
|
||||
| Target and Pathway | |||||
| Target(s) | Aminopeptidase N | Target Info | Inhibitor | [522549], [530043] | |
| Dipeptidyl peptidase IV | Target Info | Inhibitor | [522549], [530043] | ||
| BioCyc Pathway | Glutathione-mediated detoxification | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | |||||
| Pathway Interaction Database | C-MYB transcription factor network | ||||
| PathWhiz Pathway | Glutathione Metabolism | ||||
| References | |||||
| Ref 522549 | ClinicalTrials.gov (NCT00824980) Combined Inhibition of Dipeptidyl Peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/CD13) in the Treatment of Psoriasis. U.S. National Institutes of Health. | ||||
| Ref 530043 | Recent insights into the role of dipeptidyl aminopeptidase IV (DPIV) and aminopeptidase N (APN) families in immune functions. Clin Chem Lab Med. 2009;47(3):253-61. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.